Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more weightbut not enough to dethrone Eli Lilly's Zepbound

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly seems too pricey right now. In contrast, Novo Nordisk seems rather cheap given. The number ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%.

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy. Read more here.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).